Sanofi Metadragon receives new indication in China for the treatment of sinus rhythm with a history of atrial fibrillation

On December 22, Sanofi announced that the National Medical Products Administration (NMPA) of China has formally approved Maidarone (dronedarone hydrochloride tablets) for paroxysmal or persistent atrial fibrillation (abbreviated as " Atrial fibrillation") patients with a history of sinus rhythm, reduce the risk of hospitalization due to atrial fibrillation

Atrial fibrillation refers to the loss of the normal rhythm of the atrial beating, which usually manifests as an irregular and rapid heart rate.

As a new type of antiarrhythmic drug, Maidarone is more effective in maintaining sinus rhythm and reducing the recurrence of atrial fibrillation.

Studies have shown that Maidarone is more effective in maintaining sinus rhythm and reducing the recurrence of atrial fibrillation

Reference materials:

[1] Just now | Sanofi's innovative drug for treatment of atrial fibrillation was approved in China.